IP Library Granted Patent US 6,890,751
Granted Patent B2
US 6,890,751 · App. 09/864,675 · Granted May 10, 2005

NRG-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,890,751
App. No.
09/864,675
Granted
May 10, 2005
Kind
B2
Abstract

The invention features methods of treatment and diagnosis using NRG-2 polypeptides, nucleic acid molecules, and antibodies. The invention also provides novel NRG-2 polypeptides and nucleic acid molecules.

Claims (19)

1. An isolated nucleic acid molecule comprising a sequence encoding a polypeptide comprising the amino acid sequence set forth in SEQ ID NOs: 2 or 4.

2. An isolated nucleic acid molecule comprising the nucleic acid sequence set forth in SEQ ID NOs: 1 or 3.

3. An isolated nucleic acid molecule consisting of the nucleic acid sequence set forth in SEQ ID NOs: 1 or 3.

4. A vector comprising the nucleic acid molecule of claim 1 , operably linked to a promoter.

5. The vector of claim 4 , wherein said vector is an expression vector.

6. A transformed host cell comprising the vector of claim 5 .

7. A vector comprising the nucleic acid molecule of claim 3 , operably linked to a promoter.

8. The vector of claim 7 , wherein said vector is an expression vector.

9. A transformed host cell comprising the vector of claim 8 .

10. A method of producing a polypeptide comprising SEQ ID NO: 2, said method comprising:

culturing a host cell comprising SEQ ID NO: 1 under conditions to express the polypeptide comprising SEQ ID NO: 2, and

purifying said polypeptide from the cell culture.

11. A method of producing a polypeptide comprising SEQ ID NO: 4, said method comprising:

culturing a host cell comprising SEQ ID NO: 3 under conditions to express the polypeptide comprising SEQ ID NO: 4, and

purifying said polypeptide from the cell culture.

12. An isolated polypeptide comprising SEQ ID NO: 2.

13. An isolated polypeptide comprising SEQ ID NO: 4.

14. An isolated polypeptide consisting of SEQ ID NO: 2.

15. An isolated polypeptide consisting of SEQ ID NO: 4.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded May 31, 2017
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: NEURONEX, INC.; CIVITAS THERAPEUTICS, INC.; ACORDA THERAPEUTICS, INC.
Reel/Frame 042643/0878 →
SECURITY INTEREST Recorded Jun 10, 2016
From: ACORDA THERAPEUTICS, INC.; CIVITAS THERAPEUTICS, INC.; NEURONEX, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 038950/0436 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 6, 2004
From: CENES PHARAMACEUTICALS, INC.
To: ACORDA THERAPEUTICS, INC.
Reel/Frame 016045/0306 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 6, 2004
From: CENES PHARAMACEUTICALS, INC.
To: ACORDA THERAPEUTICS, INC.
Reel/Frame 016075/0942 →